We presented data on our gene-edited therapy for people with sickle cell disease or transfusion-dependent beta thalassemia at the European Hematology Association (EHA) Congress and announced regulatory submissions for potential future use in additional patients. Find out more: https://vrtx.com/en-global/

We’re grateful to the researchers, clinicians, and patients whose contributions help move the science forward.

#EHA2026